In RA synovial fluid, neutrophils rely on Anxa1, with elevated levels of Anxa1 in microvesicles, and induce TGF‐β1 production via its receptor, FPR2/ALX, thereby protecting cartilage.[126] Prior bioinformatics analyses also support Anxa1's protective role in OA,[127] where nucleus pulposus cells (NPC) seek inflammation relief from neutrophils via the Anxa1‐FPR1 pathway, suggesting Anxa1 as a potential therapeutic target for Intervertebral Disc Degeneration (IDD).[128] These findings highlight the cartilage‐protective role of Anxa1 in peripheral joint diseases, such as RA and IDD. This evidence concerns the gene TGFB1 and intervertebral disk degenerative disorder.